Augmented Rififylin Is a Risk Factor Linked to Aberrant Cardiomyocyte Function, Short-QT Interval and Hypertension

Physiological Genomics Laboratory, Department of Physiology and Pharmacology, University of Toledo College of Medicine, 3000 Arlington Ave, Toledo, OH 43614-2598, USA.
Hypertension (Impact Factor: 7.63). 02/2011; 57(4):764-71. DOI: 10.1161/HYPERTENSIONAHA.110.165803
Source: PubMed

ABSTRACT Using congenic strains of the Dahl salt-sensitive (S) rat introgressed with genomic segments from the normotensive Lewis rat, a blood pressure quantitative trait locus was previously mapped within 104 kb on chromosome 10. The goal of the current study was to conduct extensive phenotypic studies and to further fine-map this locus. At 14 weeks of age, the blood pressure of the congenic rats fed a low-salt diet was significantly higher by 47 mm Hg (P<0.001) compared with that of the S rat. A time-course study showed that the blood pressure effect was significant from very young ages of 50 to 52 days (13 mm Hg; P<0.01). The congenic strain implanted with electrocardiography transmitters demonstrated shorter-QT intervals and increased heart rate compared with S rats (P<0.01). The average survival of the congenic strain was shorter (134 days) compared with the S rat (175 days; P<0.0007). The critical region was narrowed to <42.5 kb containing 171 variants and a single gene, rififylin. Both the mRNA and protein levels of rififylin were significantly higher in the hearts of the congenic strain. Overexpression of rififylin is known to delay endocytic recycling. Endocytic recycling of fluorescently labeled holotransferrin from cardiomyocytes of the congenic strain was slower than that of S rats (P<0.01). Frequency of cardiomyocyte beats in the congenic strain (62±9 bpm) was significantly higher than that of the S rat (24±6 bpm; P<0.001). Taken together, our study provides evidence to suggest that early perturbations in endocytic recycling caused by the overexpression of Rffl is a novel physiological mechanism potentially underlying the development of hypertension.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Genome-wide association studies (GWAS) have prioritized a transcription factor, nuclear receptor 2 family 2 ( NR2F2), as being associated with essential hypertension in humans. Here we provide evidence that validates this association and indicates that Nr2f2 is a genetic determinant of blood pressure (BP). Using the zinc-finger nuclease technology, the generation of a targeted Nr2f2-edited rat model is reported. The resulting gene-edited rats have a 15 bp deletion in exon 2 leading to a five-amino-acid deletion in the hinge region of the mutant Nr2f2 protein. Both systolic and diastolic blood pressures of the Nr2f2mutant rats are significantly lower than controls. Because the hinge region of Nr2f2 is required for interaction with Friend of Gata2 ( Fog2), protein–protein interaction is examined. Interaction of Nr2f2mutant protein with Fog2 is greater than that with the wild-type Nr2f2, indicating that the extent of interaction between these two transcription factors critically influences BP.
    Nature Communications 02/2015; 6. DOI:10.1038/ncomms7252 · 10.74 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Two recent studies [Newton-Cheh et al., Nature Genetics 41, 399-406 (2009); Pfeufer et al., Nature Genetics 41, 407-414 (2009)] identified an association, with genome-wide significance, between a single nucleotide polymorphism within the gene encoding RING finger protein 207 (RNF207) and the QT interval. We sought to determine the role of RNF207 in cardiac electrophysiology. Morpholino knockdown of RNF207 in zebrafish embryos resulted in APD prolongation, occasionally a 2:1 atrioventricular block and slowing of conduction velocity. Conversely, neonatal rabbit cardiomyocytes infected with RNF207-expressing adenovirus exhibited shortened APD. Using transfections of U-2 OS and HEK293 cells, western blot and immunocytochemistry data demonstrate that RNF207 and the HERG (human ether-a-go-go-related gene) potassium channel interact and co-localize. Furthermore, RNF207 overexpression significantly elevated total and membrane HERG protein and HERG-encoded current density by approximately 30-50%, which was dependent on the intact N-terminal RING domain of RNF207. Finally, co-expression of RNF207 and HSP70 increased HERG expression as compared to HSP70 alone. This effect was dependent on the C-terminus of RNF207. Taken together, the evidence is strong that RNF207 is an important regulator of action potential duration likely via effects on HERG trafficking and localization in a heat shock protein-dependent manner.
    Journal of Biological Chemistry 10/2014; 289(49). DOI:10.1074/jbc.M114.592295 · 4.60 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Heart failure is a life-threatening condition that carries a considerable emotional and socio-economic burden. As a result of the global increase in the ageing population, sedentary life-style, increased prevalence of risk factors, and improved survival from cardiovascular events, the incidence of heart failure will continue to rise. Despite the advances in current cardiovascular therapies, many patients are not suitable for or may not benefit from conventional treatments. Thus, more effective therapies are required. Transforming growth factor (TGF) β family of cytokines is involved in heart development and dys-regulated TGFβ signalling is commonly associated with fibrosis, aberrant angiogenesis and accelerated progression into heart failure. Therefore, a potential therapeutic pathway is to modulate TGFβ signalling; however, broad blockage of TGFβ signalling may cause unwanted side effects due to its pivotal role in tissue homeostasis. We found that leucine-rich α-2 glycoprotein 1 (LRG1) promotes blood vessel formation via regulating the context-dependent endothelial TGFβ signalling. This review will focus on the interaction between LRG1 and TGFβ signalling, their involvement in the pathogenesis of heart failure, and the potential for LRG1 to function as a novel therapeutic target.
    Biophysical Reviews 03/2015; 7(1). DOI:10.1007/s12551-014-0158-y

Full-text (2 Sources)

Available from
May 30, 2014

Kathirvel Gopalakrishnan